 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for AIFM2 |
 Gene summary |
| Basic gene information | Gene symbol | AIFM2 |
| Gene name | apoptosis-inducing factor, mitochondrion-associated, 2 | |
| Synonyms | AMID|PRG3 | |
| Cytomap | UCSC genome browser: 10q22.1 | |
| Type of gene | protein-coding | |
| RefGenes | NM_032797.5, NM_001198696.1, | |
| Description | apoptosis-inducing factor (AIF)-homologous mitochondrion-associated inducer of deathapoptosis-inducing factor (AIF)-like mitochondrion-associated inducer of deathapoptosis-inducing factor 2p53-responsive gene 3 protein | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 605159 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000042286 | ||
| HPRD : 09797 | ||
| Vega : OTTHUMG00000018398 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_AIFM2 | |
| BioGPS: 84883 | ||
| Pathway | NCI Pathway Interaction Database: AIFM2 | |
| KEGG: AIFM2 | ||
| REACTOME: AIFM2 | ||
| Pathway Commons: AIFM2 | ||
| Context | iHOP: AIFM2 | |
| ligand binding site mutation search in PubMed: AIFM2 | ||
| UCL Cancer Institute: AIFM2 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | BreastCervix | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | BRCACESC | |
| Reference showing the relevant tissue of AIFM2 | ||
| Description by TissGene annotations | Cancer gene TissgsLTS | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0008637 | apoptotic mitochondrial changes | 11980907 | GO:0043065 | positive regulation of apoptotic process | 11980907 | GO:0008637 | apoptotic mitochondrial changes | 11980907 | GO:0043065 | positive regulation of apoptotic process | 11980907 |
| Top |
| TissGeneExp for AIFM2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| BRCA | -0.539635496 | 1.137434679 | -1.677070175 | 3.70E-26 | 3.90E-25 |
| PRAD | -1.254781346 | -0.180715962 | -1.074065385 | 1.30E-17 | 3.24E-15 |
| Top |
| TissGene-miRNA for AIFM2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for AIFM2 |
| TissGeneSNV for AIFM2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.G117D | PAAD | 1 |
| p.S362C | BLCA | 1 |
| p.L241V | BLCA | 1 |
| p.I85V | LGG | 1 |
| p.R143Q | UCEC | 1 |
| p.A180T | UCEC | 1 |
| p.V306M | STAD | 1 |
| p.A295D | UCEC | 1 |
| p.S258N | OV | 1 |
| p.V122F | BLCA | 1 |
| p.S187F | LUSC | 1 |
| p.P101L | SKCM | 1 |
| p.R208W | CESC | 1 |
| p.G113V | LUAD | 1 |
| p.V82L | LUAD | 1 |
| p.P166L | ESCA | 1 |
| p.A108T | UCEC | 1 |
| p.E219A | UCEC | 1 |
| p.G154E | SKCM | 1 |
| p.A320T | PAAD | 1 |
| p.M135T | COAD | 1 |
| p.P101S | SKCM | 1 |
| p.V35I | UCEC | 1 |
| p.L318V | BRCA | 1 |
| p.N218S | STAD | 1 |
| p.R54Q | UCEC | 1 |
| p.H104Y | BLCA | 1 |
| p.T236S | SKCM | 1 |
| p.T327M | HNSC | 1 |
| p.S68F | BRCA | 1 |
| p.D86Y | READ | 1 |
| p.V146M | UCEC | 1 |
| p.S152L | DLBC | 1 |
| p.V289M | UCEC | 1 |
| p.R316Q | PRAD | 1 |
| p.P323L | KIRP | 1 |
| Top |
| TissGeneCNV for AIFM2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for AIFM2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | NA | AV704263 | AIFM2-GAS7 | chr10:71873495 | chr17:9817154 | |
| Chimerdb3.0 | ChiTaRs | NA | CB164713 | AIFM2-AIFM2 | chr10:71892565 | chr10:71873742 |
| Top |
| TissGeneNet for AIFM2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| Top |
| TissGeneProg for AIFM2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for AIFM2 |
| TissGeneDrug for AIFM2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for AIFM2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C1140680 | Malignant neoplasm of ovary | 2 | BeFree,GAD |
| umls:C0029925 | Ovarian Carcinoma | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |